期刊文献+

HPLC测定利奈唑胺原料药中3个降解杂质 被引量:1

Determination of Three Degradation Impurities in Linezolid Bulk Drug by HPLC
下载PDF
导出
摘要 目的建立测定利奈唑胺原料药中3种主要降解杂质的高效液相色谱(HPLC)法。方法采用ZORBAX SB-C_(18)(4.6 mm×250 mm,5 μm)色谱柱,以0.1 %三氟乙酸乙腈溶液-0.1 %三氟乙酸水溶液为流动相,线性梯度洗脱,检测波长254 nm,流速1.0 ml/min,柱温30℃,进样量10 μl。结果利奈唑胺与杂质Ⅰ、杂质Ⅱ、杂质Ⅲ的线性范围分别为0.1072~10.72 μg/ml (r=1.0000),0.1026~10.26 μg/ml(r=0.9999),0.1033~10.33 μg/ml (r=0.9999),0.1015~10.15 μg/ml (r=0.9998);利奈唑胺与杂质Ⅰ、杂质Ⅱ、杂质Ⅲ的定量限分别为0.032,0.031,0.031,0.030 μg/ml;检测限分别为0.011,0.010,0.010,0.010 μg/ml;3种杂质平均回收率分别为97.36 %,96.76 %和95.54 %,RSD分别为1.62%,1.22%和1.82%。结论该方法简便灵敏,结果准确可靠,重复性好,可用于利奈唑胺有关物质的控制。 Objective To establish an HPLC method for the assay of three degradation impurities in linezolid bulk drug.Methods A ZORBAX SB-C_(18)(4.6 mm×250 mm, 5 μm) column was used,using 0.1 % trifluoroacetic acid acetonitrile solution-0.1 % trifluoroacetic acid aqueous solution as mobile phase of linear gradient elution.The detection wavelength was set at 254 nm.The flow rate was 1.0 ml/min and the column temperature was 30 ℃.The injection volume was 10 μl. Results The calibration curves of linezolid,impurity Ⅰ,Ⅱ and Ⅲ showed good linearities in the range of 0.1072-10.72 μg/ml(r=1.0000),0.1026-10.26 μg/ml(r=0.9999),0.1033-10.33 μg/ml(r=0.9999) and0.1015-10.15 μg/ml(r=0.9998),respectively.The LOQs for linezolid,impurity Ⅰ,Ⅱ and Ⅲ were 0.032,0.031,0.031 and 0.030 μg/ml,respectively;LODs were 0.011,0.010,0.010 and 0.010 μg/ml,respectively. The average recoveries for three degradation impurities were 97.36 %, 96.76 % and 95.54 %, with RSDs of 1.62 %, 1.22 % and1.82%. Conclusion The method is simple,sensitive,accurate and reproducible,and can be used for control of related substance in linezolid bulk drug.
作者 彭相君 于丽萍 路易 PENG Xiang-jun;YU Li-ping;LU Yi(Rizhao Second People’s Hospital,Rizhao 276807,China;Shandong New Times Pharmaceutical Co.,Ltd.,Linyin 273400,China)
出处 《食品与药品》 CAS 2021年第4期342-347,共6页 Food and Drug
关键词 利奈唑胺 降解杂质 高效液相色谱 含量测定 linezolid degradation product HPLC determination
  • 相关文献

参考文献9

二级参考文献85

  • 1DIEKENA DI, JONES RN. Oxazolidinones: a review [ J ]. Drugs, 2000,59( 1 ) :7 - 16.
  • 2MOELLERING RC JR. Linezolid:the first oxazolidinone antimicrobial[ J], Ann Intern Med,2003,138(2) :135 - 142.
  • 3MEAGHER AK, FORREST A, RAYNER CA, et al. Population pharmacoklnetics of linezalid in patients treated in a compassionate-use program [ J ]. Antimicrob Agents Chemother, 2003,47 ( 2 ) : 548 - 553.
  • 4JANKOWSKI A, STEFANI KW. Linezolid-novel antibiotic for the treatment of gram-positive bacterial infections [ J ]. Wiad Lek, 2006,59(9/10) :727 -731.
  • 5RICHARD G, WUNDERINK MD, JORDI RELLO,et al. Linezolid vs Vancomycin. Analysis of two double-blinded studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia[ J ]. Chest,2003,124 ( 5 ) : 1789 - 1797.
  • 6ZEANA C, KUBIN C J, LA-LATTA P,et al. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid :case report and review of the literature[ J]. Clin Infect Dis, 2001,33 ( 15 ) :477 - 482.
  • 7AMENT PW, JAMSHED N, HOME JP. Linezolid : its role in the treatment of gram-positive,drug-resistant bacterial infections[ J ]. Am Fam Physician ,2002,65 (4) :663 - 670,
  • 8HAMEL JC, STAPERT D, MOERMAN JK, et al. Linezolid, critical characterstics[ J]. Infection,2000,28 ( 1 ) :60 - 64.
  • 9STALKER DJ,JUNGBLUTH GL. Clinical pharmacokinetics of linezolld, a novel oxazolidinone antlbacterial [ J ]. Clin Pharrnacokinet,2003,42 ( 13 ) : 1129 - 1140.
  • 10SCHROEDER TH ,HANSEN M, STEPHAN M ,et al. Elimination of linezolid by an in vitro extracorporeal circuit mode [ J ]. Int J Artif Organs ,2004,27 ( 6 )473 - 479.

共引文献108

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部